Company Overview
Snapshot
Founded in August 2013 by Ofer Shalev and Rafael Hof, New Phase operates with 11–50 employees. The company has raised $35 million across three funding rounds. In June 2024, New Phase received FDA approval for clinical trials in the U.S. for its groundbreaking cancer treatment.
Business overview
New Phase is a Health Tech & Life Sciences company focused on developing breakthrough solutions in Oncology. The company's core technology is a Nanotechnology System designed to treat metastatic solid tumors by delivering thermal energy to malignant cells, causing cancer cell death via electromagnetic hyperthermia without harming healthy tissues. This technology, which can act as a stand-alone treatment, aims to prolong patient life by turning cancer into a manageable chronic ailment. New Phase serves the healthcare industry, particularly providers and pharmaceutical companies, with its Sarah Nanoparticles (SaNPs) and Electromagnetic Induction System (EIS).
Strategic signal
In June 2024, New Phase secured FDA approval for clinical trials in the U.S. for its novel cancer treatment. This milestone is a significant validation of the company's nanotechnology system, signaling strong regulatory confidence and opening a critical pathway for market expansion and further clinical development in a major healthcare market. For investors, this indicates a de-risking event and potential for accelerated growth and commercialization.
Log in to access full profile ›Company Intelligence Q&A
- What is New Phase's core technology?
- New Phase's core technology is a nanotechnology system that uses proprietary Sarah Nanoparticles (SaNPs) and an Electromagnetic Induction System (EIS) to deliver thermal energy to metastatic solid tumors, causing cancer cell death via electromagnetic hyperthermia.
- When did New Phase receive FDA approval for clinical trials in the U.S.?
- In June 2024, New Phase received FDA approval for clinical trials in the U.S. for its cancer treatment technology.
- What was a key development for New Phase in October 2025?
- In October 2025, New Phase was highlighted for its approach to transforming treatment outcomes by heating tumors at the cellular level.
- What was the focus of New Phase's preclinical trials in April 2016?
- In April 2016, New Phase successfully completed small mammal preclinical trials for a cancer treatment designed to transform cancer into a treatable chronic ailment.
- What was a notable leadership change at New Phase in November 2021?
- In November 2021, a former Hadassah chief joined New Phase, strengthening its leadership team in tumor treatment development.